BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Asia/Shanghai
BEGIN:STANDARD
TZOFFSETFROM:+0800
TZOFFSETTO:+0800
TZNAME:CST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210428
DTEND;VALUE=DATE:20210430
DTSTAMP:20260515T035129
CREATED:20210208T082114Z
LAST-MODIFIED:20210208T082114Z
UID:28846-1619568000-1619740799@www.pharmajournalist.com
SUMMARY:Triple Negative Breast Cancer Drug Development Digital Summit
DESCRIPTION:Improving the Safety\, Efficacy & Predictability of Monotherapy & Combinatorial Therapies to Fast-track the Discovery & Development of TNBC Treatments to Reach Patients in Need \nThis is the primary industry platform specifically dedicated to providing you insight into the latest developments of safe and efficacious blockbuster therapies to treat triple negative breast cancer. \nBreast cancer (BC) is the most common solid tumor in women\, with the triple negative subtype associated with poorer overall survival and a higher probability of cancer recurrence. \nGiven the large unmet clinical need in this oncology indication and aligned with recent clinical trial progress\, the Triple Negative Breast Cancer (TNBC) Drug Development Digital Summit has been created to provide insight into industry- and academic-led clinical programs developing immune checkpoint\, DDR inhibitor\, ADC and other novel agents. \nThis is the industry’s definitive conference specifically dedicated to advancing the development of both monotherapy and combinatorial therapies to improve the current standard of care for patients with TNBC. \nJoin leading experts from CytoDyn\, Zenith Epigenetics\, Oncorus\, University of Pittsburgh and more who are identifying specific molecular targets\, such as immune checkpoint modulators\, intra-nuclear targets\, intracellular targets\, and cell surface targets\, to limit the progression and metastasis of this invasive tumor and improve patient outcomes. \nWhether you are developing a TROP2-ADC\, a PARP inhibitor\, a viral immunotherapy or a cancer vaccine for treating TNBC\, this dedicated digital meeting is your opportunity to discuss novel\, cutting edge targeted therapies in TNBC and get a full picture of the clinical landscape. \nTo know more about Triple Negative Breast Cancer Drug Development Digital Summit please click here.
URL:https://www.pharmajournalist.com/event/triple-negative-breast-cancer-drug-development-digital-summit/
LOCATION:Virtual/Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210428
DTEND;VALUE=DATE:20210430
DTSTAMP:20260515T035129
CREATED:20210222T084218Z
LAST-MODIFIED:20210222T084218Z
UID:29072-1619568000-1619740799@www.pharmajournalist.com
SUMMARY:The 4th Global NASH Congress
DESCRIPTION:The Global NASH Congress programme creates a collaborative environment in which you can create enduring relationships across the full range of disciplines engaged in NASH research & drug discovery and development. \n \n\nLearn how to integrate NAFLD Screening into secondary and tertiary care\nDiscover the regulatory pathways for approval of biomarkers in NAFLD patients\nReview the current and potential biomarkers for staging\nInvestigate if targeting fructose metabolism offers a NAFLD/NASH therapy\nHear how belapectin\, a galectin-3 (Gal-3) inhibitor\, is in development for the prevention of oesophagal varices in patients with NASH cirrhosis\nExplore the Epidemiology of NAFLD\n\nTo know more about The 4th Global NASH Congress please click here.
URL:https://www.pharmajournalist.com/event/the-4th-global-nash-congress/
LOCATION:Online & on-demand
ORGANIZER;CN="Global Engage":MAILTO:nnoakes@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210504
DTEND;VALUE=DATE:20210507
DTSTAMP:20260515T035129
CREATED:20210203T083221Z
LAST-MODIFIED:20210203T083221Z
UID:28753-1620086400-1620345599@www.pharmajournalist.com
SUMMARY:Multi-Functional Cell Therapies Summit
DESCRIPTION:Advance Cutting-Edge Research and Development with Next-Generation Cell Therapies\, to Deliver Best-in-Class Products to Patients in Need\nCell therapies hold life-saving potential for patients\, and the race is on to develop best-in-class\, living\, ‘thinking’ drugs. Relapse rates and barriers to solid tumor efficacy mean the cell therapy industry must innovate\, now more than ever.  \nThe inaugural Multi-Functional Cell Therapies Summit gathers the avantgarde to discuss strategies to weaponize cell therapies with antigenic\, engineered and combination approaches to create sophisticated\, multi-functional systems. \nFor more details about the program\, speaker faculty or pricing and discounts\, download the brochure.
URL:https://www.pharmajournalist.com/event/multi-functional-cell-therapies-summit/
LOCATION:EST | Digital
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210505
DTEND;VALUE=DATE:20210507
DTSTAMP:20260515T035129
CREATED:20210121T121615Z
LAST-MODIFIED:20210121T121835Z
UID:28605-1620172800-1620345599@www.pharmajournalist.com
SUMMARY:Chronic Hepatitis B Drug Development Summit
DESCRIPTION:The first ever meeting purpose-built for discussing the advancement of curative therapies for chronic HBV infection.  \nFeaturing an all-star speaker faculty from across industry\, NGOs and academia\, all dedicated to finding a curative therapy for Chronic HBV infection.  This is a unique opportunity to review the latest clinical investigations with novel and classic therapeutics including RNAi and immuno-therapies. \n \nHere is just a snapshot of some of the speakers who are joining us: \nYuchun Nie\, Senior scientist\, Aligos Therapeutics\nGaston Picchio\, Chief Development Officer\, Arbutus Biopharma\nWilliam Delaney\, Chief Scientific Officer\, Virology\, Assembly Biosciences (USA)\nStephane Daffis\, Scientist II\, Gilead Sciences\nPatricia Mendez\, Vice President – Clinical Development\, Immunocore Ltd\nAndrew Vaillant\, Chief Scientific Officer\, Replicor Inc.\nTom Evans\, Chief Scientific Officer\, Vaccitech\nDavid Anderson\, Chief Scientific Officer\, VBI Vaccines Inc. \nDon’t miss out on this opportunity to benchmark yourself against the competition\, get a comprehensive update on how the field stands and network with peers from across the field at the inaugural Chronic Hepatitis B Drug Development Summit.  Find out more >> https://ter.li/haruyt
URL:https://www.pharmajournalist.com/event/chronic-hepatitis-b-drug-development-summit/
LOCATION:Virtual Summit
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210510
DTEND;VALUE=DATE:20210512
DTSTAMP:20260515T035129
CREATED:20210205T092218Z
LAST-MODIFIED:20210205T092218Z
UID:28774-1620604800-1620777599@www.pharmajournalist.com
SUMMARY:SMi’s 5th Annual Highly Potent Active Pharmaceutical Ingredients Conference (HPAPi)
DESCRIPTION:Innovations in HPAPI Containment & Facility Design for Successful Manufacturing \nSponsored by: Catalent Pharma Solutions and FPS Food and Pharma Systems \nChaired by: Justin Mason-Home\, Director\, HPAPI Project Services Limited \nSMi is delighted to announce its 5th Annual Highly Potent Active Pharmaceutical Ingredients Virtual Conference on 10th and 11th May 2021. \n \nHighly Potent Active Pharmaceutical Ingredients (HPAPIs) play an increasing central role in the fight against many diseases. There is an increasing need to protect workers who handle HPAPIs along the life cycle of the drug product manufacturing\, from synthesis of the pharmaceutical active ingredient to distribution of the finished medicinal product. This year’s event will focus on 4 key themes: best practices for toxicological assessment\, innovations in containment and facility design\, advances in the use of robotics and automation in manufacturing processes\, and environmental considerations. Key case studies will be highlighted throughout these themes\, revealing the key challenges for current HPAPI manufacture\, and insights into the latest technological and regulatory advances in this increasingly potent environment. \nAttend the conference and join our networking platform for industry professionals to provide you with the expertise to overcome the challenges of the HPAPi industry. \nKey Speakers for HPAPi include: \n\nEster Lovsin-Barle\, Head of Product Stewardship and Health\, Takeda\nRichard Denk\, Senior Consultant Aseptic Processing & Containment\, SKAN AG\nRaphael Nudelman\, Director of Chemical & Computational Toxicology\, Teva Pharmaceutical\nOlindo Lazzaro\, Director Global EHS\, AbbVie\nFred Ohsiek\, Senior Specialist\, Cleaning Validation\, Novo Nordisk\nFlorian Grundmann\, MSAT Team Lead\, Cleaning Validation\, Roche\nIldiko Ziegler\, QA Manager\, Vanessa Research\nJack Brown\, Senior Research Fellow\, formerly Boehringer Ingelheim\nReinhold Maeck\, Head of Corp EHS Regulatory Intelligence\, Boehringer Ingelheim\n\nDoreen Parrish\, Head of Corporate Audit\, Global EHS\, Takeda \nKey Reasons to Attend HPAPi: \n\nExplore best practices in hazard assessment and occupational toxicology\nunderstand strategic considerations for planning pilot plants and scaling up manufacturing capabilities for high potency compounds\ndiscover potential for automation and robotics in pharmaceutical manufacturing and technologies for protecting operators from hazardous substances\ndiscuss the opportunities for effective CDMO relationships and explore methods for strengthening those partnerships\nDelve into the expanding ADC market within and beyond oncology\nVirtual conference benefits include virtual exhibition booths packed with information\, networking features to chat and share contact details with attendees\n\nView the full agenda: www.highlypotentapi.com/PJwl
URL:https://www.pharmajournalist.com/event/smis-5th-annual-highly-potent-active-pharmaceutical-ingredients-conference-hpapi/
LOCATION:Online Access Only
ORGANIZER;CN="SMi Events":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210510
DTEND;VALUE=DATE:20210512
DTSTAMP:20260515T035129
CREATED:20210305T123955Z
LAST-MODIFIED:20210308T094548Z
UID:29277-1620604800-1620777599@www.pharmajournalist.com
SUMMARY:SMi’s 21st Annual Pain Therapeutics Conference
DESCRIPTION:Sponsored by: MD Biosciences and Transpharmation \nChaired by Michael Scherz\, Founder & CEO\, Metys Pharma and Naheed Mirza\, Early Development Pain & CNS Specialist \nExplore Cutting Edge Drug Discovery Science and Key Clinical-Stage Pain Therapies in the Pipeline \nSMi’s 21st Pain Therapeutics Conference will focus on looking into research within pain therapeutics. In particular\, the long-term (HEAL) initiative will be discussed and its role in advancing research to reduce the risks of opioid use and misuse and improve pain management\, thereby reducing reliance on opioids and the national opioid public health crisis.  Talks will also address the importance of sex\, gender and race in pain research\, including biomarkers\, molecular targets\, clinical and experimental models of pain. \n \nThe conference also address cutting edge drug discovery science\, preclinical development trends\, analysis of key clinical-stage pain therapies\, with a focus on highlighting the importance of biomarker discovery and its contribution to early stage studies on pain. This will be topped off with a panel debate on rethinking pain clinical trials during the COVID-19 pandemic. And further look into treating painful osteoarthritis of the knee with a novel anti NGF\, anti-TNFα bispecific fusion protein as well as therapeutic novelties signifying a paradigm shift in migraine prevention. Additionally\, the conference will explore Botulinum neurotoxin\, Sigma 1 proteins and AP-325 as novel treatment for neuropathic pain as well as the high unmet medical need to develop a novel non-drowsy skeletal muscle relaxant and explore pain genetics in rare diseases as well as the Opioid Crisis and the future of addiction and Pain Therapeutics. \nJoin Europe’s leading Pain Therapeutics Virtual Conference in May 2021 to explore cutting edge drug discovery science and key clinical-stage pain therapies in the pipeline\, bringing together leading pharmaceutical companies and to discuss solutions for the challenges of clinical trial design and conduct.\n#SMiPain \nKey Reasons to Attend the Conference: \n\nDiscover which innovative new therapies are driving clinical development including case studies from Novaramed and Vapogenix\nExamine the best strategies to generate more funding in pain research clinical trials to eliminate the issue of underfunding\nExplore how COVID-19 has changed the experience of clinical trials and presented an opportunity to reform the way we approach data verification\, data analysis and data collection\nUnderstand the role of biomarkers in evaluating target engagement of new drugs and predicting analgesic efficacy\nVirtual Conference Benefits include virtual exhibition booths packed with information\, networking features to chat and share contact details with other attendees\, and virtual meetings and networking socials.\n\nWHO SHOULD ATTEND \nChief Executive Officer\, Chief Scientific Officers\, Chief Medical Officers\, Managing Directors\, CEO\, Head of Department\, Principal Research Scientists\, Clinical lead\, Clinical Operations in the following fields: \n\nPain and Migraine\nInflammation\nChronic Pain\nNeuropathic Pain\nAnalgesic pre-clinical development\nAnaesthesia and Pain Management\nCNS clinical trials\nIon Channel Pharmacology\nPharmacology Intelligence\nTranslational science\nDrug development\nExploratory development\n\nView the full agenda: http://www.pain-therapeutics.co.uk/PJwl
URL:https://www.pharmajournalist.com/event/smis-21st-annual-pain-therapeutics-conference/
LOCATION:Virtual Conference – Online Access Only
ORGANIZER;CN="SMi Group":MAILTO:EVENTS@SMI-ONLINE.CO.UK
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210511
DTEND;VALUE=DATE:20210514
DTSTAMP:20260515T035129
CREATED:20210208T104245Z
LAST-MODIFIED:20210208T104245Z
UID:28869-1620691200-1620950399@www.pharmajournalist.com
SUMMARY:Manufacturing Assets and Facility Management in Pharma Summit 2021
DESCRIPTION:Manufacturing Assets and Facility Management in Pharma Summit returns in 2021. Taking place virtually this May 11-13\, a must attend event to help modernize your facility and revitalize your asset management strategies. Join this cutting-edge discussion and network with engineering\, maintenance and manufacturing facilities leaders. \nTo know more about Manufacturing Assets and Facility Management in Pharma Summit 2021 please click here.
URL:https://www.pharmajournalist.com/event/manufacturing-assets-and-facility-management-in-pharma-summit-2021/
LOCATION:Virtual Conference
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210512
DTEND;VALUE=DATE:20210514
DTSTAMP:20260515T035129
CREATED:20200108T084240Z
LAST-MODIFIED:20200604T152104Z
UID:23563-1620777600-1620950399@www.pharmajournalist.com
SUMMARY:Injectable Drug Delivery 2021
DESCRIPTION:Assessing the innovations in formulations and devices for enhanced injectable delivery  \nSMi Group is pleased to announce the third annual Injectable Drug Delivery conference\, which will be held in London on the 12th and 13th May 2021. \nPart of Europe’s leading Injectable conference series\, Injectable Drug Delivery will assess innovations in drug product formulation and biologics\, innovations in device design\, quality management and connectivity for enhanced subcutaneous delivery. \n \nWith rapid developments in the parenteral space\, the injectable drug delivery market is set to reach USD 902.3 billion by 2027\, with an increased focus on patient centricity during DDC development and innovations in device development\, including new therapeutic applications such as the delivery of siRNA. This year’s event will focus on advances in drug product formulation and innovations of device design and development to aid delivery. \nFurthermore\, the conference will assess the evolving regulatory environment of injectable drug delivery with industry and regulatory representatives presenting updates on current guidelines. \nThe two-day agenda also offers peer-to-peer networking with Global Product Managers\, Device Testing Managers\, Senior Device Engineers\, Heads of Device Development\, Heads of Formulation and Drug Process Development\, and many more. \nThe benefits of attending: \nThis conference offers a chance to learn about innovative injectable drug delivery systems with industrial insights on the following: \n\nDELVE into the latest work in complex formulation for subcutaneous delivery\nBENCHMARK against leading pharma companies working to enhance device design and development\nUNDERSTAND the regulatory environment of the injectables space from leading regulatory and industry advisors\nENGAGE in industry case studies on design controls\, human factors and parenteral formulation\nEXPLORE advances in connectivity and human factors key learnings in two pre-conference workshops\n\nWho should attend: \nExecutives\, Directors\, VPs\, Heads\, Principals\, Managers\, Scientists\, Researchers of: \n\nAutoinjectors\nWearables\nDevice Engineering\nHuman Factors\nCMC\nInjectables\nSterile Manufacturing\nPackaging\nRegulatory Affairs\n\nFeatured Speakers: \n\nAlexander Zuern\, Device testing manager\, Novartis International AG\nAndrew Warrington\, Project Leader & Patient Advocate\, Novartis\nBenjamin Werner\, Scientist\, Boehringer Ingelheim Pharma GmbH & Co. KG\nBjorg K Hunter\, Regulatory Manager\, Devices\, GSK\nBlake Green\, Senior Manager Regulatory Affairs\, Amgen\nCamille Dagallier\, Formulation and Drug Process Development Senior Scientist\, Sanofi\nChristopher Muenzer\, Senior Device Technology Manager\, Novartis\nJoel Richard\, Head of Technical & Pharmaceutical Operations\, MedinCell\nMark Palmer\, Scientific Leader\, Biopharm Device Engineering\, GSK\nRebecca Moses\, Director\, Core Human Factors Inc.\nRupal Nguyen\, Principal Engineer\, Allergan\nStefania Ragone\, Pharmaceutical Assessor\, Medicines & Healthcare Products Regulatory Agency (MHRA)\nTina Arien\, Principal Scientist\, Janssen Pharmaceutica\nVikas Jaitely\, Director\, Global Regulatory Affairs Transitional Medicine and Devices\, Merck\n\nLinkedIn: @SMi Pharma\nTwitter: @SMiPharm #SMiInjectables
URL:https://www.pharmajournalist.com/event/injectable-drug-delivery-2021/
LOCATION:St. James’ Court\, 54 Buckingham Gate\, Westminster\, London\, SW1E 6AF\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210518
DTEND;VALUE=DATE:20210521
DTSTAMP:20260515T035129
CREATED:20210211T103519Z
LAST-MODIFIED:20210211T103816Z
UID:28913-1621296000-1621555199@www.pharmajournalist.com
SUMMARY:Genetic Vaccine Development for Infectious Diseases Summit
DESCRIPTION:The COVID-19 pandemic brought life-changing disruptions to people around the world and has turned the typical vaccine R&D process on its head. A combination of urgent need\, unprecedented investments\, and advances in genetic engineering has allowed what was once mere speculation to become not only our reality\, but our future. \n \nWith pandemic vaccines now launching at record speeds\, the first Genetic Vaccine Development for Infectious Diseases Summit will focus on overcoming the translational and clinical challenges of developing genetic vaccines targeting infectious diseases\, including Influenza\, Lassa fever\, Ebola\, MERS\, HIV\, Zika\, and COVID-19. \nWith a focus on mRNA\, DNA\, and engineered viral vector-based vaccines\, this niche 3-day agenda has been specifically designed to help industry experts to discuss new genetic-based vaccine platforms\, preclinical and clinical case studies\, optimized delivery methods\, and the future of vaccine R&D to usher in a new era of vaccinology\, with experts from BioNTech\, Pfizer\, Moderna\, AstraZeneca and CureVac. \nTo know more about Genetic Vaccine Development for Infectious Diseases Summit please\nclick here.
URL:https://www.pharmajournalist.com/event/genetic-vaccine-development-for-infectious-diseases-summit/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210520
DTEND;VALUE=DATE:20210522
DTSTAMP:20260515T035129
CREATED:20210226T102847Z
LAST-MODIFIED:20210226T102847Z
UID:29162-1621468800-1621641599@www.pharmajournalist.com
SUMMARY:5th Annual MarketsandMarkets Bioprocessing of Biotherapeutics-UK\,EU & APAC-Virtual
DESCRIPTION:After the successful four editions of Bioprocessing of Cell therapies\, coming up with 5th Annual of Bioprocessing of Biotherapeutics brings together leading bioprocessing scientists to share day-to-day challenges and practical solutions for the development\, manufacture and quality of protein expressions\, cell\, and gene therapies. \nThe virtual event will present detailed case studies and interactive discussions in cell culture\, scale-up\, continuous processing\, recovery\, purification\, process and product characterization\, and formulation. \nEvent Website: https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-bioprocessing-of-biotherapeutics-uk-eu-apac-virtual/ \nRegistration link:  https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-bioprocessing-of-biotherapeutics-uk-eu-apac-virtual/register 
URL:https://www.pharmajournalist.com/event/5th-annual-marketsandmarkets-bioprocessing-of-biotherapeutics-ukeu-apac-virtual/
LOCATION:Virtual Event
ORGANIZER;CN="Marketsandmarkets":MAILTO:Shardul.oza@marketsandmarkets.com, events@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210525
DTEND;VALUE=DATE:20210528
DTSTAMP:20260515T035129
CREATED:20201210T121300Z
LAST-MODIFIED:20201210T121300Z
UID:28242-1621900800-1622159999@www.pharmajournalist.com
SUMMARY:Ligase Targeting Drug Development – Digital Summit
DESCRIPTION:As the therapeutic value of manipulating previously hard-to-drug ubiquitin ligases becomes more and more evident in addressing numerous diseases with unmet clinical needs\, the inaugural Ligase Targeting Drug Development Summit arrives as the dedicated scientific and networking forum for large pharma\, innovative biotech and research institutes to seize the day. \n \nBuilt with large pharma and biotech insight\, the Ligase Targeting Drug Development Summit is fully dedicated to enabling novel ligase discovery and characterization\, achieving cell and tissue specificity and expanding chemical biology tools to therapeutically leverage ubiquitin ligases for effective protein modulation or degradation strategies. \nAs leading pharma companies join forces to bridge the gap between the functional knowledge and true translational value of ubiquitin ligases and their associated ligands\, join us to advance your understanding\, differentiate your pipelines and tap into the uncapped therapeutic potentials of this emerging field. \nTo know more about Ligase Targeting Drug Development – Digital Summit please click here.
URL:https://www.pharmajournalist.com/event/ligase-targeting-drug-development-digital-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210525
DTEND;VALUE=DATE:20210528
DTSTAMP:20260515T035129
CREATED:20210118T161111Z
LAST-MODIFIED:20210118T161111Z
UID:28556-1621900800-1622159999@www.pharmajournalist.com
SUMMARY:Gene Therapy for Muscular Disorders
DESCRIPTION:With clinical holds lifting there has been more investment and clinical progress in the gene therapy for muscular disorders space than ever before\, yet the consequences of toxicity are not a distant memory. Despite the successes\, there are still withstanding challenges for gene therapy developers targeting the muscle when it comes to optimizing delivery and navigating toxicity to develop truly safe and transformative therapeutics for muscular disorders patients. \n \nThe first industry-dedicated Gene Therapy for Muscular Disorders Summit will focus on overcoming the translational and clinical challenges of developing genetic therapies targeting muscular disorders\, including Duchenne Muscular Dystrophy (DMD)\, Limb-Girdle Muscular Dystrophy (LGMD)\, Pompe Disease and X-Linked Myotubular Myopathy. \nWith a focus on AAV and gene editing technologies and insights from Pfizer\, Solid Biosciences\, Audentes and Vertex\, this niche 3-day agenda has been specifically designed to help industry experts to: \n\nOptimize your promoter choice and navigate IP challenges for more efficient delivery to muscular targets\nDiscover the next generation capsids being developed for improved muscle selectivity and reduced immunogenic responses\nUnderstand the biology of different immunogenic responses and hear feedback from trialled strategies to ensure optimal patient safety\nHear the latest research in muscular disorder biomarkers\nDefine clinically meaningful muscular endpoints to successfully and objectively measure muscular disease improvement\nTackle regulatory challenges to demonstrate gene therapy durability\nOvercome clinical challenges to manage patient heterogeneity for patient centric and meaningful trials\n\nJoin your peers to share\, learn and discuss at the first industry-focused Gene Therapy for Muscular Disorders. Overcome your immunogenicity challenges and mitigate toxicity with high doses targeting the muscle to successfully demonstrate durability with your gene therapy product. \nTo know more about Gene Therapy for Muscular Disorders please click here.
URL:https://www.pharmajournalist.com/event/gene-therapy-for-muscular-disorders/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210525
DTEND;VALUE=DATE:20210528
DTSTAMP:20260515T035129
CREATED:20210208T082747Z
LAST-MODIFIED:20210208T090154Z
UID:28850-1621900800-1622159999@www.pharmajournalist.com
SUMMARY:3rd Microbiome Movement – Maternal & Infant Health Summit 2021
DESCRIPTION:Harness the Maternal-Infant Microbiome\, Establish New Mechanisms of Action\, and Develop Breakthrough Health Products that Proactively Prevent Disease Risk  \nReturning for another year\, this platform will unite industry and academics in the exploration of preventative and therapeutic treatment of the microbiome during pregnancy and early life. The discussion during this 3-day conference will cover key periods of pregnancy\, birth and infant development to encompass a range of areas where therapeutic\, nutritional targeting and research can be undertaken. \nTake this opportunity to join the event and you can:   \n\nGain a complete understanding of the current research and therapeutic opportunities as we walk through the infant journey from in utero development through to the first 1000 days\nUnderstand the value of the mother’s experience and health for foetal development with talks from Siobhain O’Mahony and Mary Claire Kimmel\nDiscover new therapeutic research into the vaginal microbiome\, such as PhagoMed and Columbia University \nBuild a broader understanding of the benefits of prevention with Evolve Biosystems highlighting cost-saving from early life treatments and the NIH’s push to advance this area of science\nHear from Siolta Therapeutics and ParetoBio in developing therapeutic treatments for allergies\n\nJoin us to further your understanding of how cutting-edge science is helping establish a causal relationship between the maternal-infant microbiome and long-term health effects\, and how this can be translated to demonstrate clinically validated solutions. \nTo know more about 3rd Microbiome Movement – Maternal & Infant Health Summit 2021 please click here.
URL:https://www.pharmajournalist.com/event/3rd-microbiome-movement-maternal-infant-health-summit-2021/
LOCATION:Virtual/Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210525
DTEND;VALUE=DATE:20210528
DTSTAMP:20260515T035129
CREATED:20210215T090719Z
LAST-MODIFIED:20210215T090719Z
UID:29000-1621900800-1622159999@www.pharmajournalist.com
SUMMARY:STING & TLR-Targeting Therapies Summit
DESCRIPTION:This is the definitive drug development forum for research teams to investigate how to modulate the cGAS-STING and Toll-like receptor (7/8/9) pathways both as monotherapies and as adjuvants in combinatorial approaches. \nThis meeting comes at a critical point for the cancer immunotherapy field\, as researchers look to increase patient response rates and the efficacy on checkpoint inhibitors in several solid tumor indications. Preclinical and early clinical data for modulators of the STING & TLR plus other innate immune checkpoint inhibitors has been hugely promising. \n \nUse this key forum to hone your innate immune activation strategies and deliver safe and effective treatments through systematic and intra-tumoral administration which can stimulate the adaptive immune arm\, counteract solid tumor-induced immunosuppression and increase response to checkpoint inhibitors. \nView the event guide for the full agenda! \nInnate Immune Checkpoints & Activation Pre-Focus Day \nIn addition to two full conference days to STING/TLR-targeting\, there will be a pre-focus day specifically on innate immune checkpoints and the activation of specific cell types including natural killer cells\, macrophages and myeloid-derived suppressor cells. \nAn executive speaker faculty will take you through the leading drug candidates aimed at inhibitory and activation receptors on key cellular component of the innate immune system. \nView the full event guide for more information.
URL:https://www.pharmajournalist.com/event/sting-tlr-targeting-therapies-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210525
DTEND;VALUE=DATE:20210528
DTSTAMP:20260515T035129
CREATED:20210312T064902Z
LAST-MODIFIED:20210312T065621Z
UID:29303-1621900800-1622159999@www.pharmajournalist.com
SUMMARY:Gene Therapy Analytical Development Europe
DESCRIPTION:In the context of unprecedented gene therapy investment and clinical progress\, with mounting regulatory scrutiny\, Gene Therapy Analytical Development Europe will unite innovative biotech and pharma organisations to develop robust analytical tools to guarantee the consistency\, quality\, and safety of gene therapy products. \n \nWhether you’re looking for specific characterisation\, potency or infectivity approaches to improve your current analytical toolbox or if you’re seeking to understand how gene therapy analytics differ from other biologics you’ve worked on in the past\, this focused\, technical event will provide insights specifically on the unique analytical challenges posed by gene therapy vectors\, delivered by ‘boots on the ground’ scientists grappling with these challenges first-hand. \nJoin 150+ analytical pioneers to discover the realities of working with tools like dPCR\, AUC and HPLC\, as well as how and where these tools can be most effective in process development\, and what the European regulators expect in order to grant approval. Whether you’re working with AAV or lentiviral vectors\, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development. \n To know more about Gene Therapy Analytical Development Europe please click here.
URL:https://www.pharmajournalist.com/event/gene-therapy-analytical-development-europe/
LOCATION:Virtual
ORGANIZER;CN="Hanson Wade":MAILTO:https://ter.li/8f5rxa
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210525
DTEND;VALUE=DATE:20210528
DTSTAMP:20260515T035129
CREATED:20210318T083358Z
LAST-MODIFIED:20210318T120953Z
UID:29402-1621900800-1622159999@www.pharmajournalist.com
SUMMARY:Inner Ear Disorders Therapeutics Summit – Digital Event
DESCRIPTION:Hearing loss has a huge impact on the quality of life for millions of people\, and as the average age of the population increases\, the need for curative life-changing therapies targeting hearing loss and inner ear disorders has never been more important. \n \nThe Inner Ear Disorders Therapeutics Summit is gathering the world’s leading biopharmaceutical companies and KOLs at the only industry-focused summit dedicated to the translation and clinical development of novel gene therapy\, cell therapy and small molecule-based approaches to treat inner ear disorders\, with the aim to progress the industry towards the first clinically approved therapy. \nJoin industry and academic experts to discuss the best preclinical modelling approaches for translative proof of concept data\, identify the most appropriate biological endpoints and overcome the major challenges to develop safe\, effective\, and clinically viable inner ear disorder therapies to address the unmet medical need. \nTo know more about Inner Ear Disorders Therapeutics Summit please click here.
URL:https://www.pharmajournalist.com/event/inner-ear-disorders-therapeutics-summit-digital-event/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210608
DTEND;VALUE=DATE:20210611
DTSTAMP:20260515T035129
CREATED:20210203T103911Z
LAST-MODIFIED:20210203T103911Z
UID:28763-1623110400-1623369599@www.pharmajournalist.com
SUMMARY:TCR-based Therapies Summit
DESCRIPTION:The TCR-based Therapies Summit is Dedicated to Supercharging TCR Design\, Translation & Manufacturing Strategy for Solid Tumor Success\nRunning digitally for 2021\, the 2nd TCR-based Therapies Summit is the leading industry-focused meeting dedicated to supercharging the expanded TCR repertoire through enhanced target specificity\, density & binding affinity for solid tumor indications. \n \nThis June (8-10)\, join this exclusive community online to virtually network and learn from the leading experts in pharma\, biotech and academia\, as we discuss how to how to overcome on-target off-tumor toxicity\, enhance the binding affinity and avidity of TCR-T therapies and utilize dual targeting and combination approaches for enhanced efficacy. \nNavigate across 3 days packed with dedicated\, interactive formats exploring the identification of novel targets\, the importance of safety profiling\, and discuss optimization of soluble approaches for the development of next-generation TCR-T products. \nFor more details about the program\, speaker faculty or pricing and discounts\, download the brochure. \nHelping Deliver Best-In-Class TCR Therapies\nJoin experts as they discuss the design\, efficacy and clinical development of TCR therapeutics for solid tumor indications and beyond. \n\nOptimizeyour TCR therapy approach\nExplorenovel combination strategies\nArmyour cells against the hostile tumor microenvironment\nImprovetarget selection and off-target validation\nExplorethe future of manufacturing for next-generation TCRs\n\n“Hanson Wade’s CAR-TCR summit has been already the leading specialized conference in the field – what a great suggestion to set up a dedicated forum for the rapidly growing TCR-T area.” \nSteffen Walter\, Chief Scientific Office\, Immatics US
URL:https://www.pharmajournalist.com/event/tcr-based-therapies-summit/
LOCATION:EST | Digital
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210608
DTEND;VALUE=DATE:20210611
DTSTAMP:20260515T035129
CREATED:20210312T065317Z
LAST-MODIFIED:20210312T065317Z
UID:29307-1623110400-1623369599@www.pharmajournalist.com
SUMMARY:Next Generation Gene Therapy Vectors
DESCRIPTION:The inaugural Next Generation Gene Therapy Vectors meeting is dedicated to overcoming the current immunogenicity\, toxicity and manufacturability challenges facing the field by pioneering the next generation of superior delivery vectors. \n \nIndustry pioneers from cutting edge biotechs and world-leading academic vectorology groups including Dyno Therapeutics\, 4D Molecular Therapeutics and Generation Bio will share how ever-increasing clinical experience is guiding strategies to decrease the immunogenicity of vectors to allow durable transgene expression\, engineer vectors with lower toxicity at higher doses and use innovative technologies to optimise capsid\, transgene\, and promoter design. \nEverything in gene therapy starts with the vector\, so join this definitive\, niche\, digital conference to delve into the details of vector design\, engineering\, and optimization case studies\, equipping you with the insights required to deliver transformative therapeutics to patients more effectively and safely than ever before. \nTo know more about Next Generation Gene Therapy Vectors please click here.
URL:https://www.pharmajournalist.com/event/next-generation-gene-therapy-vectors/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210613
DTEND;VALUE=DATE:20210616
DTSTAMP:20260515T035129
CREATED:20210401T075326Z
LAST-MODIFIED:20210401T075326Z
UID:29614-1623542400-1623801599@www.pharmajournalist.com
SUMMARY:9th PREDiCT: Tumor Models Cell Therapy Summit
DESCRIPTION:With commitments to advancing your preclinical and translational oncology research\, we are delighted to bring the 9th annual PREDiCT: Tumor Models Cell Therapy Summit to your screens in July. \nSee best-in-class tumor models and how they can be effectively utilized to model the tumor microenvironment and further your MoA understanding for new cell therapies. \nLearn to improve your translational and clinical confidence through the use of models to answer critical safety and efficacy questions\, predict toxicity and optimize dosing for patients. \nWhether you work in early discovery or late development\, there is something for all non-clinical professionals with two dedicated tracks: one focused on preclinical modelling and one looking at translational studies. \nBelow are a few highlights you won’t want to miss! \n\nNovartisshare how to use a simple xenograft model to effectively assess CAR-T efficacy\nAstraZenecashows how to guide innovative clinical trials for cell therapies using preclinical data\nTakedadiscuss how to leverage single-cell analytics to understand the complexities of the tumor microenvironment\nHarvard Medical Schoolshare how they use multiple tumor models to advance NK cell therapies\n\nGet involved! Our scientific poster sessions will be returning this year so you can share your latest advances and be apart of the conversation. \nTo know more about 9th PREDiCT: Tumor Models Cell Therapy Summit please click here.
URL:https://www.pharmajournalist.com/event/9th-predict-tumor-models-cell-therapy-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210614
DTEND;VALUE=DATE:20210616
DTSTAMP:20260515T035129
CREATED:20190206T211230Z
LAST-MODIFIED:20200330T122307Z
UID:19393-1623628800-1623801599@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes West Coast
DESCRIPTION:SMi are proud to announce the 5th annual conference:\nPre-Filled Syringes West Coast 2020\n14-15 June 2021\nSan Diego\, CA\, USA\nHyatt Regency Mission Bay\nwww.prefilled-syringes-westcoast.com/pjwl \nAssessing Device Development and Regulation for Advanced Innovation \nSMi is proud to present the 5th Annual Pre-Filled Syringes West Coast Conference in San Diego on 14th and 15th June 2021. \n \nFollowing the success of the last event\, the Pre-Filled Syringes West Coast conference is back to uncover the latest innovations in combination product development\, device design\, human factors engineering and drug product formulation to give a holistic overview of the industry and what we can expect for the future. \nWith the global market for prefilled syringes estimated to exceed $9.7bn by 2025\, this year’s agenda will encompass key drivers and hot topics of the industry including; updates to regulatory guidance from industry experts and regulatory bodies\, case studies on device design and complex formulation\, life cycle and control strategies\, and innovations in connectivity and digital health. \nThis two-day agenda offers you peer-to-peer networking with Global Product Managers\, Senior PFS Engineers\, Device Testing Managers\, Heads of Late-Stage PFS Development and many more. \nPLUS\, two interactive post conference workshops: \nWorkshop A: Connected devices and digital health: How to navigate the US FDA usability engineering requirements\nHosted by Shannon Clark\, Principal\, UserWise\, Inc. \nWorkshop B: Postmarket safety reporting: The current regulatory environment with a global impact\nHosted by Khaudeja Bano\, Sr. Medical Director\, Abbott Molecular  \nKey Reasons to Attend: \n\nEngage in case study presentations from leading pharma and biotech companies on complex product formulation and optimising device design to aid delivery\nDiscuss show to optimise current processes to align with global regulatory updates\nDelve into human factors engineering best practices\nUncover how industry is incorporating connectivity and digital health to optimise the user experience \n\nWho should attend: \n\nDrug-delivery developers\nMedical Device Engineers\nPrimary Packaging material designers\nSecondary packagers\nSmart device developers\nTraining device developers\nDevice-safety solution providers\nDrug developers \n\nEarly bird deadlines: \n\nRegister by 28th February to save $400\nRegister by 31st March to save $200\nRegister by 30th April to save $100\n\n\nTo register or for more information visit: www.prefilled-syringes-westcoast.com/pjwl \nSOCIAL MEDIA HANDLES \nTwitter: @SMiPharm #Smipfsusa\nLinkedIn: follow our company page – search ‘SMi Pharma’
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-west-coast/
LOCATION:Hyatt Regency Mission Bay\, 1441 Quivira Road\, San Diego\, CA\, 92109\, United States
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210615
DTEND;VALUE=DATE:20210618
DTSTAMP:20260515T035129
CREATED:20210212T080535Z
LAST-MODIFIED:20210212T080535Z
UID:28924-1623715200-1623974399@www.pharmajournalist.com
SUMMARY:2nd RNAi-Based Therapeutics – Digital Summit
DESCRIPTION:As investments and collaborations hit a record high\, the RNAi therapeutics industry continues to rapidly expand. With RNAi drugs prevailing as a therapy with huge potential against liver diseases\, exciting efforts have now turned to a wide range of other diseases\, from CNS\, oncology\, metabolism and more. Despite the growing momentum\, much needs to be addressed in terms of targeted delivery\, safety\, and efficiency to fully unleash the therapeutic value of RNAi drugs. \n \nBuilt with large pharma and pioneering biotech insights\, the 2nd RNAi- Based Therapeutics Summit returns virtually in 2021 to reunite key stakeholders of the field to tap into the full therapeutic opportunity of a wide-range of targeted RNAi therapies with enhanced endosomal escape\, extrahepatic delivery\, & PKPD for CNS\, oncology & beyond. \nWith a number of RNAi based clinical candidates emerging and excitement building in the field\, join the 2nd RNAi Based Therapeutic Summit 2021 – the comprehensive industry guide for senior biopharmaceutical leaders from discovery\, translation & clinical development functions to stay ahead of the race in developing the first targeted extrahepatic RNAi therapy that addresses unmet patient need. \nTo know more about 2nd RNAi-Based Therapeutics please click here.
URL:https://www.pharmajournalist.com/event/2nd-rnai-based-therapeutics-digital-summit/
LOCATION:Digital Event\, EDT
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210616
DTEND;VALUE=DATE:20210618
DTSTAMP:20260515T035129
CREATED:20201020T102522Z
LAST-MODIFIED:20201020T102824Z
UID:27546-1623801600-1623974399@www.pharmajournalist.com
SUMMARY:Skin Microbiome Summit
DESCRIPTION:Skin microbiome products have been gaining more momentum in the last few years with more brands starting to develop products\, and personal care giants either starting to develop their own product or investing in start-ups focusing on these. It is a very exciting time for companies looking into this at the moment\, figuring out not only product development & formulation but also marketing strategy to raise more attention to this type of products. Despite huge popularity and early success stories\, there is still a need to learn more on topics such as: defining the skin microbiome\, formulating products\, cosmetics & pharma claims\, regulation for novel products\, latest advances in terms of mapping & profiling technologies\, as well as product testing. \n \nACI’s Skin Microbiome Industry Summit\, taking place on the 16th & 17th June 2021 in London\, will bring together the key actors of the industry to help the industry learn from one another\, work together to further grow and create new business opportunities. \nDuring the 2 days conference\, the participants will enjoy the various case studies presentations\, panel discussion\, Q&As and networking breaks to get the industry to thrive together. \nJoin us in London for a highly interactive & informative conference\, whilst enjoying the networking opportunities with your peers. \nMembers are entitled to a special discount on registration – to claim please contact Adamantia (Mado) Lampropoulou on MLampropoulou@acieu.net or +44 (0) 203 141 0607 quoting SSMe1MKTG.
URL:https://www.pharmajournalist.com/event/skin-microbiome-summit/
LOCATION:Park Plaza Westminster Bridge 200 Westminster Bridge Rd\, Bishop’s London\, SE1 7UT\, United Kingdom
ORGANIZER;CN="Active Communications International (ACI)":MAILTO:Mlampropoulou@acieu.net
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210617
DTEND;VALUE=DATE:20210619
DTSTAMP:20260515T035129
CREATED:20190131T121650Z
LAST-MODIFIED:20200608T143856Z
UID:19291-1623888000-1624060799@www.pharmajournalist.com
SUMMARY:Pharmaceutical Microbiology West Coast
DESCRIPTION:SMi’s 4th Pharmaceutical Microbiology West Coast Conference \nNovel approaches and best practices for tackling current industry contamination control challenges \nSMi’s 4th Annual Conference Pharmaceutical Microbiology West Coast\nNEW DATE: June 17 – 18\, 2021\nLocation: Hyatt Regency Mission Bay Hotel\, San Diego\, CA\, USA\nWebsite: http://www.pharma-microbiology-usa.com \n \nSPONSORED BY: Associates of Cape Cod\, bioMérieux\, Bioscience International\, Microcoat\, Millipore Sigma and Mettler Toledo \nCo-chairs Jim Polarine\, Senior Technical Service Manager\, STERIS Corporation & Geeta Singh\, Plant and Network Technical Specialist III\, Genentech \nFollowing on the success of the last West Coast event\, SMi proudly presents the 4th Pharmaceutical Microbiology West Coast Conference\, in San Diego\, USA\, on June 17th and 18th 2021 bringing microbiology experts to focus on innovations in rapid methods and contamination control strategies. Microbes such as bacteria\, fungi\, parasites and viruses that can contaminate current and novel pharmaceutical products or therapies may stem from various sources such as raw materials and human operators\, are taken into consideration. \nThis concern is critical in advanced products/therapeutics facilities where often distinct areas within manufacturing are slowly merging\, providing potential new sites for contamination events. The conference showcases sessions that cover alternative endotoxin testing and rapid mycoplasma testing as well as implementation of in-line biodurden monitoring to control water systems\, to name a few. Due to the complexities brought about by more advanced therapeutic products\, both drugs and patients are time dependent and rapid methods are ever more desired. \nA significant portion of the conference will focus on contamination control strategies and facilities support/novel technologies such as a look at a sustainable global contamination control program\, cleanroom pass thru best practices and a case study executing rapid transition from clinical to commercial manufacturing and more. Also see a regulatory session discussing objectionable organisms in non-sterile drug products and an all-women panel discussion: ‘culturing’ successful women microbiologists. \nEvent Hashtag: #SMiPharmaMicroWC \nKEY HIGHLIGHTS FOR 2021 INCLUDE: \n\nDiscuss the guidance\, regulations and case studies for objectionable organisms in non-sterile drug products from ValSource\, Inc.\nGain insight into changing paradigms – moving to in-process testing from Johnson & Johnson\nExamine alternative endotoxin test methods for products exhibiting LER from Amgen\nExplore how to effectively scale up from clinical to commercial in three moves from Bristol-Myers Squibb\nJoin us for our first All-Women Panel Discussion on ‘Culturing’ successful women microbiologists\n\nPlus a half day interactive workshop on Wednesday\, June 16th 2021: \nAfternoon Workshop: Data Integrity in Environmental Monitoring: Causes and Solutions \nLed by: Ziva Abraham\, CEO\, Microrite and Morgan Polen\, SME\, Cleanroom Contamination Control Expert\, Microrite \nView the full agenda: http://www.pharma-microbiology-usa.com \nWHO SHOULD ATTEND \nSenior Microbiologist\, Lead Scientist\, Laboratory Manager\, QA Specialist Drug Substance External Manufacturer\, Business Development Manager – Testing\, Pharmaceutical Microbiology Consultant\, Higher Pharmacopoeia Scientist\, Analytical Standards Specialist \nSOCIAL MEDIA HANDLES \nTwitter: @SMiPharm\nEvent Hashtag: #SMiPharmaMicroWC\nLinkedIn: follow our company page – search ‘SMi Pharma’ \nADDITIONAL CONTACT INFO\nSimi Sapal – Marketing Manager\nPharmaceutical Division – SMi Group Ltd\nT: +44 (0)20 7827 6100\nE: ssapal@smi-online.co.uk
URL:https://www.pharmajournalist.com/event/pharmaceutical-microbiology-west-coast/
LOCATION:Hyatt Regency Mission Bay Hotel\, 1441 Quivira Road\, San Diego\, CA\, CA 92109\, United States
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210617
DTEND;VALUE=DATE:20210618
DTSTAMP:20260515T035129
CREATED:20210617T072629Z
LAST-MODIFIED:20210617T072629Z
UID:30572-1623888000-1623974399@www.pharmajournalist.com
SUMMARY:6th Annual Oncolytic Virotherapy Summit
DESCRIPTION:In its most exciting year yet the field of oncolytic virotherapy has seen the highest number of clinical read-outs\, the emergence of next generation viruses\, and never-before-seen combination therapies. \nNow in its 6th year\, the Oncolytic Virotherapy Summit is the industry’s definitive guide to turning viral vehicles into clinically effective therapeutics across oncology indications. With 3 days of in-depth cutting-edge case studies and the highest caliber of industry discussions\, The OV Summit will provide the roadmap to oncolytic virotherapy market success. \n \nUncover fresh studies from pharma and biotech companies of all sizes\, as well as clinicians and leading academics for a complete picture of the current challenges and opportunities. \nThis year’s Summit will help you to: \n\nUnderstand how viral backbone modification can achieve intravenous delivery\nHarness carefully selected payloads to achieve systemic effects\nScale virus production for commercialization\nThis year\, over 100+ drug developers will converge at the OV Summit to disseminate the latest findings\, build a comprehensive network of like-minded peers who share the same challenges and search for the latest combination and genetic engineering strategies.\n\nJoin the leading minds in oncolytic virus development to optimize the development of viral immunotherapies and improve patient outcomes in combination therapies.
URL:https://www.pharmajournalist.com/event/6th-annual-oncolytic-virotherapy-summit/
LOCATION:Westin Copley Place\, 10 Huntington Ave\, Boston\, MA\, MA 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210622
DTEND;VALUE=DATE:20210625
DTSTAMP:20260515T035129
CREATED:20210315T105128Z
LAST-MODIFIED:20210315T105128Z
UID:29391-1624320000-1624579199@www.pharmajournalist.com
SUMMARY:HER2-Targeted Therapies Summit 2021
DESCRIPTION:Welcome to the Digital HER2-Targeted Therapies Summit 2021 – The First Conference Focused on Exploring New Frontiers of HER2 as a Pan-Tumor Target \nHER2 expressing patients are experiencing drug resistance\, suboptimal duration of response and refractory/relapsed disease\, stimulating new frontiers for HER2-targeted drug development. Impressive clinical data are being reported for next-generation anti-HER2 approaches in breast\, gastric\, lung\, colon cancers and beyond. However\, efforts to expand the clinical utility of HER2 as a pan-tumor target don’t stop there\, with a flood of news on priority reviews\, fast track approvals\, IPOs and collaborations. \nAs such\, the HER2-Targeted Therapies Digital Summit 2021 arrives as the first ever cross-disciplinary meeting for large pharma\, biotech and academia\, to maximize HER2-targeting in the pantumor setting. Expect to be involved in interactive discussions on the diversity of next generation anti-HER2 drugs in the clinic including ADCs\, bispecifics\, TKIs\, CAR approaches & more. \nThis is your chance to overcome challenges of resistance against anti-HER2 approaches and accelerate therapies to patients in need. Examine HER2 heterogeneity across different tumors to maximize the commercial potential of this target. Discuss how quantitative pathology is helping to match HER2 expression with therapeutic response. \nAs the clinical and commercial growth potential of next generation HER2-targeted therapies becomes apparent\, this is a timely and comprehensive forum giving you the opportunity to connect with leaders of the field directly. \nBe part of this unique forum to strengthen your pipeline by expanding the clinical utility of your anti-HER2 candidate across tumor settings with the greatest unmet medical need. \nTo know more about HER2-Targeted Therapies Summit 2021 please click here.
URL:https://www.pharmajournalist.com/event/her2-targeted-therapies-summit-2021/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Shanghai:20210622T150000
DTEND;TZID=Asia/Shanghai:20210622T190000
DTSTAMP:20260515T035129
CREATED:20210602T080240Z
LAST-MODIFIED:20210602T080240Z
UID:30412-1624374000-1624388400@www.pharmajournalist.com
SUMMARY:CPhI & P-MEC China E-Trade Season- Sino-India Pharmaceutical Exchange
DESCRIPTION:CPhI & P-MEC China has launched the “E-Trade Season 2021” from March to June 2021 to provide the pharmaceutical industry with online learning and trading opportunities. One of the themed sessions\, named Sino-India Pharmaceutical Exchange\, will be focusing on Indian & Chinese pharma markets\, with online learning and trading opportunities. \nThe live stream webinar will look into policies\, trends and practice\, etc. of both Chinese and Indian pharma markets\, covering topics including Development Trend of China’s API Industry and Cooperation Prospect with India\, Requirements and Practical Procedures of Imported Drug Registration in China\, and Development of Indian APIs and Generic Drugs in Indian and Chinese Market\, with guest speakers from China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE)\, China Chinopharma Limited\, and Dr. Reddy’s Laboratories. \nThe webinar is FREE for anyone to register and attend. Registered attendees will receive access to the webinar.
URL:https://www.pharmajournalist.com/event/cphi-p-mec-china-e-trade-season-sino-india-pharmaceutical-exchange/
LOCATION:Online
ORGANIZER;CN="Informa Markets":MAILTO:tinny.yao@imsinoexpo.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210628
DTEND;VALUE=DATE:20210701
DTSTAMP:20260515T035129
CREATED:20210402T091212Z
LAST-MODIFIED:20210406T095308Z
UID:29618-1624838400-1625097599@www.pharmajournalist.com
SUMMARY:3rd Annual Blood-Brain Barrier Summit
DESCRIPTION:Now in its 3rd year\, the Blood-Brain Barrier Summit is the industry’s definitive blood-brain barrier conference\, focused exclusively on evaluating innovative approaches to tackling the single biggest challenge for CNS drug developers. \nBuilding on the success of last year’s meeting\, this year’s program will uncover how leading companies and academics are working to enhance BBB penetration through the use of antibody therapies\, nanoparticle engineering\, AAV capsids\, focused ultrasound\, extracellular vesicles and more! New for this year we also explore the mechanisms of SARS-CoV-2 brain entry. \nAs we gather the best minds in this ever-challenging field\, from the likes of AbbVie\, Novartis\, Roche\, Merck and Ossianix\, join this intimate forum to be part of the conversation focused on enhancing drug delivery across the blood-brain barrier and network and build meaningful partnerships with over 80 blood-brain barrier specialists. \nTo know more about 3rd Annual Blood-Brain Barrier Summit please click here.
URL:https://www.pharmajournalist.com/event/blood-brain-barrier-summit-2021/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210629
DTEND;VALUE=DATE:20210702
DTSTAMP:20260515T035129
CREATED:20210301T091950Z
LAST-MODIFIED:20210301T091950Z
UID:29192-1624924800-1625183999@www.pharmajournalist.com
SUMMARY:6th Microbiome Movement - Drug Development Summit
DESCRIPTION:Close the Clinical Gap\, Discover the Next Generation of Microbiome-based Therapeutics\, and Establish New Partnerships to Accelerate Your Research \nThe advancing scientific and clinical landscape mixed with the high-quality audience that we bring together has made this the must attend conference for those translating microbiome science into clinically successful therapeutics. \nThere is increased excitement around this years’ discussion; the community is now closer than ever to the first approved and commercially available microbiome-based therapeutic\, key functions are beginning to be understood and the number of clinical candidates are increasing. However\, there still remains an abundance of significant hurdles that must be overcome in order for continued success to be seen within the microbiome field. We are proud to bring together those at the forefront of tackling those challenges and is once again the centre of the 6th Microbiome Movement – Drug Development Summit. \n \nThe Microbiome Movement will provide the perfect opportunity for a collaborative approach between the biopharmaceutical and academic communities in order to pursue the causal role of the microbiome in disease and develop a new generation of microbiome-targeted therapeutics with predictable modes of action and consistent clinical outcomes. \nFrom understanding microbiome functionality\, leveraging lessons from clinical development and scaling manufacturing processes\, through to leveraging microbiome biomarkers for patient stratification and diagnostics\, our discussion will cover the latest scientific findings and industry updates from the end-to-end development of microbiome therapeutics. \nThere is still so much we can continue to do to make this complex science a clinical reality that improves the lives of patients\, and we hope that you can join this years’ discussion to help towards the development of effective treatments across a range of indications and push microbiome products closer to commercialization. \nTo know more about 6th Microbiome Movement – Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/6th-microbiome-movement-drug-development-summit/
LOCATION:Virtual
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210629
DTEND;VALUE=DATE:20210702
DTSTAMP:20260515T035129
CREATED:20210309T092319Z
LAST-MODIFIED:20210309T092319Z
UID:29289-1624924800-1625183999@www.pharmajournalist.com
SUMMARY:Induced Proximity-Based Drug Discovery Summit
DESCRIPTION:Since the start of the 20th century\, there have been three major waves of innovation in drug discovery. We are now at the start of a fourth wave\, multispecific medicines\, that will pave the way for new treatments aimed at thousands of disease targets currently viewed as “undruggable”. By inducing proximity between two or more proteins\, multispecifics can harness the power of biology to go well beyond what conventional drugs can achieve. \n \nAs such\, the inaugural Induced Proximity-Based Drug Discovery Summit arrives as the dedicated scientific and networking forum for large pharma\, innovative biotech and research institutes to seize the endless potential of induced proximity- based drug discovery strategies to develop novel therapies for paradigm changing multispecific drugs of the future. \nJoin 100+ thought leaders of Chemically Biology\, Screening Biology and Molecular Biology from the likes of Amgen\, Ranok Therapeutics\, Proxygen and more at the Induced Proximity- Based Drug Discovery Summit to advance your knowledge\, differentiate your pipelines and be at the forefront of this new wave of innovation that will revolutionize drug discovery as currently known. \nTo know more about Induced Proximity-Based Drug Discovery Summit please click here.
URL:https://www.pharmajournalist.com/event/induced-proximity-based-drug-discovery-summit/
LOCATION:EST | Digital
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210629
DTEND;VALUE=DATE:20210702
DTSTAMP:20260515T035129
CREATED:20210312T075616Z
LAST-MODIFIED:20210312T080030Z
UID:29331-1624924800-1625183999@www.pharmajournalist.com
SUMMARY:JAK Inhibitors Drug Development Summit
DESCRIPTION:Returning to the digital stage this summer\, the 2nd JAK Inhibitors Drug Development Summit brings you the only dedicated JAK inhibitor conference that will allow you to utilize the knowledge of the greatest minds and thought leaders within the realms of the JAK pathway across dermatology\, rheumatology\, gastroenterology\, oncology and hematology. \nFocusing on optimized selectivity\, drug-drug interactions\, safety and efficacy challenges\, this summit will give you the insight to successfully translate and develop the next generation of superior JAK inhibitors. \nEnsure you attend this conference to learn\, to network and to strengthen your pipeline\, and implement the right clinical strategy.
URL:https://www.pharmajournalist.com/event/jak-inhibitors-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR